Martin Pruschy Selected Research

epothilone B (EPO906)

4/2015	Combined treatment strategies for microtubule stabilizing agent-resistant tumors.
7/2014	Ionizing radiation induces tumor cell lysyl oxidase secretion.
4/2013	The microtubule stabilizer patupilone counteracts ionizing radiation-induced matrix metalloproteinase activity and tumor cell invasion.
1/2012	Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial.
1/2012	Dynamics of tumor hypoxia in response to patupilone and ionizing radiation.
9/2011	Regulation of VEGF-expression by patupilone and ionizing radiation in lung adenocarcinoma cells.
9/2011	The microtubule stabilizer patupilone (epothilone B) is a potent radiosensitizer in medulloblastoma cells.
6/2011	Metabolism of tumors under treatment: mapping of metabolites with quantitative bioluminescence.
2/2009	Role of the microenvironment for radiosensitization by patupilone.
2/2005	Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Martin Pruschy Research Topics

Disease

47	Neoplasms (Cancer) 04/2022 - 02/2004
10	Hypoxia (Hypoxemia) 06/2021 - 06/2006
8	Carcinoma (Carcinomatosis) 01/2016 - 08/2005
5	Medulloblastoma 05/2018 - 01/2009
4	Glioblastoma (Glioblastoma Multiforme) 01/2018 - 01/2012
3	Head and Neck Neoplasms (Head and Neck Cancer) 01/2020 - 12/2017
3	Glioma (Gliomas) 01/2018 - 01/2012
3	Colonic Neoplasms (Colon Cancer) 01/2017 - 02/2005
3	Adenocarcinoma of Lung 04/2015 - 09/2011
2	Hypersensitivity (Allergy) 04/2022 - 01/2014
2	Residual Neoplasm 01/2020 - 02/2011
2	Squamous Cell Carcinoma of Head and Neck 12/2017 - 07/2007
1	Lymphopenia (Lymphocytopenia) 01/2022
1	Rhabdomyosarcoma 01/2021
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2020
1	Malignant Mesothelioma 01/2018
1	Melanoma (Melanoma, Malignant) 01/2016
1	Sarcoma (Soft Tissue Sarcoma) 01/2016
1	Neoplasm Metastasis (Metastasis) 07/2014
1	Chromosome Aberrations (Chromosome Abnormalities) 01/2014
1	Memory Disorders (Memory Loss) 09/2013
1	Fibrosarcoma 04/2013
1	Mesothelioma 12/2012
1	Starvation 12/2012

Drug/Important Bio-Agent (IBA)

10	epothilone B (EPO906)IBA 04/2015 - 02/2005
6	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2017 - 02/2004
6	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 06/2011 - 02/2004
5	Protons (Proton)IBA 04/2022 - 01/2014
5	Phosphotransferases (Kinase)IBA 05/2018 - 08/2004
5	Excipients (Suspending Agents)IBA 04/2015 - 06/2011
4	Biomarkers (Surrogate Marker)IBA 06/2021 - 06/2011
4	Pharmaceutical PreparationsIBA 01/2021 - 01/2012
4	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 06/2006
4	TubulinIBA 01/2017 - 02/2005
4	vatalanib (PTK787)IBA 06/2011 - 02/2004
3	Radiation-Sensitizing AgentsIBA 06/2021 - 02/2005
3	Biological ProductsIBA 06/2021 - 04/2017
3	Oxygen (Dioxygen)IBA 01/2021 - 01/2012
3	DNA (Deoxyribonucleic Acid)IBA 03/2020 - 10/2011
3	Paclitaxel (Taxol)FDA LinkGeneric 01/2017 - 02/2005
3	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 01/2017 - 02/2005
3	taxaneIBA 01/2017 - 02/2005
3	Tyrosine Kinase InhibitorsIBA 06/2011 - 06/2006
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 10/2008 - 06/2006
2	Metalloproteases (Metalloproteinases)IBA 01/2021 - 04/2013
2	Antineoplastic Agents (Antineoplastics)IBA 03/2020 - 01/2007
2	Cisplatin (Platino)FDA LinkGeneric 01/2020 - 12/2012
2	Cetuximab (Erbitux)FDA Link 01/2020 - 01/2020
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2020 - 12/2017
2	Bevacizumab (Avastin)FDA Link 10/2017 - 04/2015
2	Messenger RNA (mRNA)IBA 09/2017 - 02/2011
2	Formaldehyde (Formol)FDA Link 01/2016 - 02/2011
2	ParaffinIBA 01/2016 - 02/2011
2	Conditioned Culture MediaIBA 07/2014 - 04/2013
2	Matrix Metalloproteinases (MMPs)IBA 07/2014 - 04/2013
2	Cytotoxins (Cytolysins)IBA 01/2012 - 01/2012
2	ErbB Receptors (EGF Receptor)IBA 08/2004 - 02/2004
2	midostaurinIBA 02/2004 - 02/2004
1	STA 9090IBA 04/2022
1	inositol trispyrophosphateIBA 01/2021
1	FenretinideIBA 01/2021
1	Hemoglobins (Hemoglobin)IBA 01/2021
1	IntegrinsIBA 05/2018
1	Blocking AntibodiesIBA 01/2018
1	Temozolomide (Temodar)FDA LinkGeneric 01/2018
1	IonsIBA 01/2018
1	LigandsIBA 01/2018
1	AntigensIBA 01/2018
1	TropomyosinIBA 09/2017
1	ProdrugsIBA 04/2017
1	TH 302IBA 04/2017
1	Oxidoreductases (Dehydrogenase)IBA 04/2017
1	lisavanbulinIBA 01/2017
1	Epothilones (Epothilone)IBA 01/2017
1	BAL27862IBA 01/2017
1	Pemetrexed (MTA)FDA Link 01/2017
1	von Willebrand FactorIBA 01/2016
1	N 30IBA 01/2016
1	Carbonic Anhydrase IXIBA 01/2016
1	Dexamethasone (Maxidex)FDA LinkGeneric 04/2015
1	Complement System Proteins (Complement)IBA 04/2015
1	AnaphylatoxinsIBA 04/2015
1	Everolimus FDA Link 04/2015
1	Angiogenesis InhibitorsIBA 04/2015
1	Transforming Growth Factors (Transforming Growth Factor)IBA 07/2014
1	Protein-Lysine 6-Oxidase (Lysyl Oxidase)IBA 07/2014
1	Small Interfering RNA (siRNA)IBA 07/2014
1	Hypoxia-Inducible Factor 1IBA 01/2014
1	BAY-84-7296IBA 01/2014
1	Cyclin D2IBA 09/2013
1	Cell ExtractsIBA 04/2013

Therapy/Procedure

17	Therapeutics 01/2020 - 06/2004
16	Radiotherapy 01/2022 - 02/2004
7	Drug Therapy (Chemotherapy) 01/2021 - 08/2005
5	Chemoradiotherapy 01/2020 - 02/2004
2	Aftercare (After-Treatment) 04/2013 - 10/2008
1	Precision Medicine 03/2020
1	Proton Therapy 01/2020
1	Immunotherapy 01/2018
1	Craniospinal Irradiation 09/2017